UTv Videos

"We wanted to see if medical recommendations for vaginal estrogen for postmenopausal women for symptom correction have a correlation with rising interest [among patients]," says Elia Abou Chawareb, MD.

“Physicians are spending, depending on how much they utilize it, 20% to 30% less time on nights and weekends,” says Ernest A. Morton, MD, MBA, MS.

“We can now see that we can find a proportion of those men that have an elevated STHLM3 tests that actually have a quite substantial risk of biochemical recurrence after the radical prostatectomy,” says Tobias Nordström, MD, PhD.

“Without Congressional action, all the progress that has been made—the new normal, so to speak—that patients, physicians, and providers alike have become used to, is at risk of potentially going back to pre-pandemic, 2019 levels,” says Juan J. Andino, MD, MBA.

“It encompasses and contains the miTNM, PROMISE, PRIMARY, RECIP, PSMA-RADS, and E-PSMA concept and criteria all together,” says Jeremie Calais, MD, PhD.

"I think [for] the consistency, we can give [a lot of] credit to the fact that Aquablation gives a lot of precision in terms of treating BPH," says Mohamad Baker Berjaoui, MD.

“We did see that there was a certain percentage of individuals who had to have dose holding, and a smaller percentage of people had to have dose reduction, in general,” says Eric Jonasch, MD.

“Overall, the take-home message is that in patients with BCG-unresponsive non–muscle-invasive bladder cancer, you can consider nadofaragene as an option among those that are available for treating these patients,” says Vikram M. Narayan, MD.

"Most of the AEs were grade 1 and 2. These consisted of frequency, urgency, UTIs—again, things we're very used to with intravesical therapies," says Siamak Daneshmand, MD.

"I think the highlights are the functional outcomes after a salvage focal ablation are favorable, definitely, compared to salvage radical prostatectomy, but the studies are quite limited in terms of real salvage focal ablation," says Kara L. Watts, MD.

"Combination therapies have now become the forefront of our field, and we are trying to do better to avoid BCG-unresponsive disease, as well as progression to either muscle-invasive or metastatic disease," says Gal Wald, MD.

"In terms of results, complete response rate at any time point for the cohort was 74.5%," says Mark D. Tyson, II, MD, MPH.

“The trial is meant to define or test this agent in this population for which currently there's not an established standard of care,” says Robert Svatek, MD.

"That gave us the idea that the diagnostic benefit of extended lymph node detection was pretty minimal," says Leilei Xia, MD.

“There was a wonderful breadth of discussion of some of the key questions that exist within management of bladder cancer right now,” says Sarah P. Psutka, MD, MSc.

"This study basically [looks at] WATER and WATER II over 5 years' follow-up," says Mohamad Baker Berjaoui, MD.

Sieber shares his thoughts on the potential for universal genetic testing to become a standard of care practice for patients with prostate cancer.

"We wanted to explore the outcomes, the compliance rates, [and] the complications with regards to Xiaflex," says Muhammed A. Moukhtar Hammad, MBBCh.

"DTC companies, especially in the men's health space, have really done a wonderful job of destigmatizing conversations," says Justin Dubin, MD.

"Saying 'no' is one of our biggest challenges in our careers as physicians," according to Phillip M. Pierorazio, MD.

"There's a ton of activity in this space, and I think every 6 to 12 months, we're going to keep getting these boluses of information that's going to help us," says Gautam Jayram, MD.

"I think that as patients go through this, it's a reminder that it's very scary," says MIchael Jenson, PA-C.

The PRESERVE trial is evaluating the safety and effectiveness of Irreversible electroporation for prostate tissue ablation.

"Things that were typically used to recruit younger physicians need to change because those aren't their priorities anymore," says Kari Bailey, MD.

"But as you get out of expert centers and academic sites that did it for years under research protocols, the level of the quality of the reads decreases," says Jeremie Calais, MD, PhD.

"Honestly, there really isn't another measure of sexual quality of life for females that addresses the specific concerns of the female partners of patients with prostate cancer," says Stacy Loeb, MD, MSc, PhD (hon).

Ernest A. Morton, MD, MBA, MS, spotlights projects looking at the use of AI scribes to assist in notetaking and an AI algorithm to analyze prostate biopsies.

"I'm hopeful that the decisions are more informed in terms of actual science," says Daniel Kwon, MD.

“I think as urologists, we need to become more comfortable with the female pelvic floor,” says Ava Saidian, MD.